The effect of resilience on bipolar mood during specialty clinic treatment.

Autor: Chiang K; The University of Texas at Austin, Dell Medical School, United States. Electronic address: kchiang@austin.utexas.edu., di Scalea TL; The University of Texas at Austin, Dell Medical School, United States., Smith T; The University of Texas at Austin, Dell Medical School, United States., Spelber D; The University of Texas at Austin, Dell Medical School, United States., Siegel-Ramsay J; The University of Texas at Austin, Dell Medical School, United States., Nemeroff CB; The University of Texas at Austin, Dell Medical School, United States., Strakowski SM; The University of Texas at Austin, Dell Medical School, United States., Almeida J; The University of Texas at Austin, Dell Medical School, United States.
Jazyk: angličtina
Zdroj: Journal of affective disorders [J Affect Disord] 2024 Feb 15; Vol. 347, pp. 314-319. Date of Electronic Publication: 2023 Nov 08.
DOI: 10.1016/j.jad.2023.11.019
Abstrakt: Background: Limitations in mental health resources behoove exploration of factors that may enhance treatment response. One such factor, resilience, has been minimally examined in bipolar disorder.
Methods: With multi-level modeling of clinical care data, we examined associations among longitudinal measurements of resilience and mood rating trajectories in a sample of 100 individuals with bipolar disorder during 6 weeks of evidence-based pharmacotherapy and psychotherapy.
Results: Individuals with high self-care subscale scores from the Resilience Questionnaire for Bipolar Disorder exhibited an improving rate of depression change -0.18 (SE = 0.04, p < .001) completing treatment with a subthreshold depression rating of 3.1 (SE = 1.39, p < .05). In contrast, treatment recipients who disagreed or were neutral towards self-care experienced worsening or no change in depression, respectively. This subscale also decreased mood elevation. Each one-point increase yielded a -0.27 (SE = 0.13 p < .05) point decrease in mania.
Limitations: Resilience may develop longitudinally. In this study, it was examined during active treatment which was a relatively brief period of time.
Conclusions: Higher bipolar resilience could identify individuals more likely to exhibit improvement in mood during bipolar specialty clinic treatment.
Competing Interests: Declaration of competing interest Charles B. Nemeroff, MD, PhD, is a consultant for ANeuroTech (division of Anima BV), Sage Therapeutics, Signant Health, Intra-Cellular Therapies, Inc., Sage Therapeutics, BioXcel Therapeutics, Silo Pharma, Engrail Therapeutics, Relmada Therapeutics, EmbarkNeuro, GoodCap Pharmaceuticals, Inc., Senseye, Inc., Pasithea Therapeutics Corp., SynapseBio, Inc., Clexio Biosciences Ltd., Ninnion, LLC., MAPS Public Benefit Corporation, Precisement Health, Lucy, EcoR1 and Galen. He is a stock shareholder (directly purchased) of Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness. Dr. Nemeroff is on the Scientific Advisory Boards for ANeuroTech (division of Anima BV), Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, and on the Board of Directors of Xhale Smart, Inc. He holds patents for the following: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). Steve Strakowski, MD, received grants/research support from Janssen Research Foundation and Sage Therapeutics and is a consultant for Sunovion (DSMB chair) and Medscape.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: